시장보고서
상품코드
1497739

세계의 바이오의약품 시장 : 시장 규모, 점유율 분석 - 동향, 촉진 요인, 경쟁 구도, 예측(2024-2030년)

Biopharmaceuticals Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

발행일: | 리서치사: Prescient & Strategic Intelligence | 페이지 정보: 영문 250 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

주요 하이라이트

세계의 바이오의약품 시장 규모는 2023년에는 4,481억 달러로 평가되었고, 2030년에는 7,451억 달러에 이를 전망이며, 7.4% 이상의 CAGR로 확대될 것으로 예측됩니다. 바이오의약품의 연구개발과 치료수용의 고조가 업계 확대의 원동력이 되고 있습니다.

항-TNF 제형의 바이오시밀러 도입 이후 유럽의 평균 비용은 약 8% 절감되었으며, G-CSF와 에리스로포이에틴의 바이오시밀러는 33-34% 삭감되었습니다. 이것은 바이오의약품이 널리 받아들여지는 도움이 되고 있습니다. 바이오의약품의 효능과 안전성은 사람들에게 신속하게 받아들여지는 결과가 되었습니다.

많은 조직과 기업들이 바이오의약품 관련 연구 개발에 주력하고 있으며, 연간 NDA/BLA 등록 수는 크게 증가하고 있습니다. 특히 감염증, 신경질환 및 암 증가에 의해 바이오의약품의 중요성이 높아지고 있습니다.

시장 인사이트

2023년 업계 점유율은 북미가 약 45%로 최대였습니다.

이 배경에는 연구개발 자금의 다과, 기술적으로 개선된 솔루션의 수용 확대, 국제 기업의 존재, 새로운 특허 취득에 중점을 두고 있는 것 등이 있습니다. 이 대륙에서는 미국이 업계를 선도하고 있습니다.

2023년에는 종양 분야가 업계를 선도해 약 40%의 점유율을 차지하였습니다. 최근 몇 년간 암 이외의 질병에 대한 시험보다 암에 대한 시험으로 바이오 의약품이 우위를 차지하고 있습니다.

세포 및 유전자 치료는 향후 몇 년동안 가장 빠른 CAGR로 성장할 것입니다. 이 분야에서는 세포 및 유전자 치료나 정밀 약제와 같은 표적 치료 등, 다양한 치료 분야의 임상시험에서 채용되고 있는 선진적인 조사에 의해 몇개의 개량이 이루어지고 있습니다.

단클론항체는 2023년에는 업계의 최대 점유율 35%를 차지하였으며, 향후 10년간은 약 7.2%의 연평균 복합 성장률(CAGR)로 더욱 추진될 전망입니다. 단클론항체(mAb)는 생물학적 제제 중 가장 중요한 부류이며 FDA가 승인한 치료제 후보의 20% 이상을 차지합니다. 일부 mAbs는 항 염증, 항암 및 기타 치료 용도로 허용됩니다. 정확하게는 암 치료에 널리 이용되고 있기 때문에 영국이나 미국과 같은 선진국에서 보급되고 있습니다.

이 보고서는 세계의 바이오의약품 시장을 분석하고 시장의 기본 구조, 최신 상황 및 주요 촉진 및 억제요인, 전 세계 및 지역별 및 주요 국가 시장 규모의 동향 전망(수량, 금액 기준, 2017-2030년), 제품 유형별, 치료 용도별 상세 동향, 현재 시장 경쟁 구도, 주요 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 지표

제5장 업계 전망

  • 시장 역학
    • 동향
    • 성장 촉진요인
    • 억제요인 및 과제
    • 성장 촉진요인 및 억제요인의 영향 분석
  • 신형 코로나 바이러스 감염(COVID-19)의 영향
  • Porter's Five Forces 분석

제6장 세계 시장

  • 개요
  • 시장 수익 : 제품 유형별(2017-2030년)
  • 시장 수익 : 치료 용도별(2017-2030년)
  • 시장 수익 : 지역별(2017-2030년)

제7장 북미 시장

  • 개요
  • 시장 수익 : 제품 유형별(2017-2030년)
  • 시장 수익 : 치료 용도별(2017-2030년)
  • 시장 수익 : 국가별(2017-2030년)

제8장 유럽 시장

제9장 아시아태평양 시장

제10장 라틴아메리카 시장

제11장 중동 및 아프리카 시장

제12장 미국 시장

  • 개요
  • 시장 수익 : 제품 유형별(2017-2030년)
  • 시장 수익 : 치료 용도별(2017-2030년)

제13장 캐나다 시장

제14장 독일 시장

제15장 프랑스 시장

제16장 영국 시장

제17장 이탈리아 시장

제18장 스페인 시장

제19장 일본 시장

제20장 중국 시장

제21장 인도 시장

제22장 호주 시장

제23장 한국 시장

제24장 브라질 시장

제25장 멕시코 시장

제26장 사우디아라비아 시장

제27장 남아프리카 시장

제28장 UAE 시장

제29장 경쟁 구도

  • 시장 진출기업 및 제공 품목의 일람
  • 주요 기업의 경쟁 벤치마킹
  • 주요 기업의 제품 벤치마킹
  • 최근의 전략 전개 상황

제30장 기업 프로파일

  • Johnson & Johnson Inc.
  • F. Hoffmann-La Roche AG
  • Pfizer Inc
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Sanofi SA
  • Eli Lilly and Company
  • Abbott Laboratories
  • AstraZeneca plc
  • Novartis AG
  • Biogen Inc.

제31장 부록

AJY 24.06.28

Key Highlights

The biopharmaceutical market generated a value of USD 448.1 billion in 2023, which will rise to USD 745.1 billion, powering at more than 7.4% compound annual growth rate, by 2030.

The surging elderly populace, the incidence of associated health problems, and the rising need for better biologic drugs are likely to create a healthy growth environment for the players.

The rising research and development as well as therapeutic acceptance of bio-based medications are driving industry expansion.

Since the introduction of biosimilars for anti-TNF products, average costs in Europe have reduced by around 8%, while biosimilars for G-CSF and erythropoietin have reduced by 33-34%.

This has aided the extensive acceptance of biopharmaceuticals. The effectiveness and safety of bio-based medications have resulted in their quick acceptance by people.

Many organizations and businesses are concentrating on R&D related to biological drugs. The number of NDAs/ BLAs registered per year has significantly increased.

With the increasing incidence of infectious diseases, neurological disorders, and cancer, the importance of biopharmaceuticals is rising.

They are utilized for treating neurodegenerative disorders, many of which necessitate bio-medications to be administered into the brain directly, which is not possible with conventional synthetic agents.

Market Insights

North America accounted for the largest share of the industry in 2023, of approximately 45%.

This is because of the high R&D funding, increasing acceptance of technologically improved solutions, the existence of international players, and their emphasis on coming up with newer patents. The U.S. led the industry in this continent.

With the development of conventional pharma sciences and biotechnology, the consciousness about the best treatments with fewer side effects has also surged.

The U.S. leads the worldwide biopharmaceutical research and development list with over 150,000 studies performed since 2008, due to the size and prominence of its pharmaceutical industry.

In the U.S., California accounts for the most studies, partly, due to its strong tech sector as well as its desire for innovation.

Oncology led the industry in 2023, with a share of approximately 40%. In the past few years, biopharmaceuticals have been dominant in cancer trials than trials for non-cancer conditions.

Cell and gene therapies will grow at the fastest compound annual growth rate in the years to come.

There have been several improvements in this area, representing advanced research, which is being employed in clinical trials in different therapeutic fields, such as cell & gene therapies and targeted therapies like precision drugs.

Monoclonal antibodies accounted for the largest share of the industry in 2023, of 35%, and it will further propel at approximately 7.2% CAGR during this decade.

Monoclonal antibodies (mAbs) are the most significant class of biologics, which account for over 20% of all the therapeutic candidates approved by the FDA.

Some mAbs have been permitted for anti-inflammatory, anti-cancer, and additional therapeutic applications. Precisely, because of their widespread utilization in cancer treatment, they are becoming widespread in developed nations like the U.K. and the U.S.

The biopharmaceutical industry is characterized by strong competition among mid-sized firms, large global firms, and new biotech firms.

Major factors boosting the competition are innovative R&D, regulatory compliance, market access, and product differentiation.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product type
    • 1.4.2. Market size breakdown, by therapeutic application
    • 1.4.3. Market size breakdown, by region
    • 1.4.4. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product Type (2017-2030)
  • 6.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product Type (2017-2030)
  • 7.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product Type (2017-2030)
  • 8.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product Type (2017-2030)
  • 9.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product Type (2017-2030)
  • 10.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product Type (2017-2030)
  • 11.3. Market Revenue, by Therapeutic Application (2017-2030)
  • 11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product Type (2017-2030)
  • 12.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product Type (2017-2030)
  • 13.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product Type (2017-2030)
  • 14.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product Type (2017-2030)
  • 15.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product Type (2017-2030)
  • 16.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product Type (2017-2030)
  • 17.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product Type (2017-2030)
  • 18.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product Type (2017-2030)
  • 19.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product Type (2017-2030)
  • 20.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product Type (2017-2030)
  • 21.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product Type (2017-2030)
  • 22.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product Type (2017-2030)
  • 23.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product Type (2017-2030)
  • 24.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product Type (2017-2030)
  • 25.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product Type (2017-2030)
  • 26.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product Type (2017-2030)
  • 27.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product Type (2017-2030)
  • 28.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Johnson & Johnson Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. F. Hoffmann-La Roche AG
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Pfizer Inc
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Merck & Co. Inc.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. AbbVie Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Sanofi SA
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Eli Lilly and Company
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Abbott Laboratories
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. AstraZeneca plc
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Novartis AG
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary
  • 30.11. Biogen Inc.
    • 30.11.1. Business overview
    • 30.11.2. Product and service offerings
    • 30.11.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제